Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab + FOLFIRI Re-challenge in mCRC
NCT02508077Phase 2Terminated
- Sponsor
- City of Hope
- Start
- Feb 2016
- Primary completion
- Sep 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in colorectal cancer (CRC), sponsored by City of Hope. Primary endpoints: 4-month Progression-free Survival Rate, Response Rate and 1 more. Started Feb 2016; status: terminated.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02508077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508077.